Clinician Innovator and Investor: Jeremy Krell, DMD (012)

Episode 12 July 21, 2021 00:44:33
Clinician Innovator and Investor: Jeremy Krell, DMD (012)
Innovation4Alpha
Clinician Innovator and Investor: Jeremy Krell, DMD (012)

Jul 21 2021 | 00:44:33

/

Show Notes

Dr. Krell is a fascinating general dentist with a combined business background. He is currently the Head of Marketing at Simplifeye, based in NYC, and the Chief Marketing Officer of Verena Solutions, based in Chicago. He oversaw provider and clinical growth initiatives at quip, the oral health and subscription electric toothbrush company, and has since built out the Barchester Bay Group, a portfolio consisting of over 15 ventures.

Jeremy practices general dentistry part-time, sits on the Boards of healthcare and dental startups, and is an angel investor. Jeremy has a 15+ year proven track record with startups through several successful multi-million dollar fundraises and acquisitions.

Jeremy started his career with three web and graphic design startups and moved into a luxury good and commodity venture, DormAid, for college students. He later founded a venture incubator, CEO in A Box, and led strategic provider innovation and development at Oscar, a national health insurance company, following his MBA at Chicago Booth.

Other Episodes

Episode 11

July 18, 2021 00:23:48
Episode Cover

Startup Profile: Eyetamins (011)

Eyetamins is a healthcare technology and life sciences company focused on therapeutics and consumer innovations in the $200B eye health and wellness space. They...

Listen

Episode 24

October 13, 2021 00:33:25
Episode Cover

Startup Profile: Embrace Prevention Care (024)

Embrace Prevention Care provides Personal Prevention Care to older adults with heart failure and other chronic conditions to help them take healthy actions that...

Listen

Episode 1

May 22, 2023 00:23:08
Episode Cover

Startup Profile: Vitro BioPharma

In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he...

Listen